Afrati Spyridoula Roberta, Lianou Ioanna, Kaspiris Angelos, Marougklianis Vasileios, Kotanidou Anastasia, Pneumaticos Spiros G
Third Department of Orthopaedic Surgery, School of Medicine, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Nikis 2, 14561 Athens, Greece.
Department of Orthopaedics, "Agios Andreas" General Hospital of Patras-NHS, 262224 Patras, Greece.
Diseases. 2025 Jul 6;13(7):212. doi: 10.3390/diseases13070212.
The incidence of postoperative pain in patients that undergo spinal interventions is significantly increased, affecting their functional outcomes and quality of life. Dexmedetomidine (DEX) belongs to the category of centrally acting nonopioid agents with highly selective α2 adrenoreceptor agonist activity that are frequently applied in spinal surgery based on its antinociceptive and anxiolytic properties. Although many studies displayed the effectiveness of DEX in postoperative pain management, the impact of DEX on functional improvement after spinal surgeries is still debatable.
This systematic review focuses on the intraoperative and postoperative role of dexmedetomidine (DEX) as an analgesic agent in elective and emergency adult spine surgery.
An electronic literature review search was conducted via Web of Science and PubMed to assess the impact of DEX on postoperative pain management, postoperative delirium (POD), and postoperative cognitive dysfunction (POCD).
Twenty-one studies were retrieved, three of which were review articles. The effects of DEX were studied for up to 48 h postoperatively. In most cases, its administration was associated with reduced intraoperative and postoperative opioid consumption. However, findings on pain control were less conclusive due to heterogeneity in dosing protocols, concomitant medications, the timing of administration, and pain scoring systems. DEX appears to reduce the incidence of POD and POCD, particularly when used in combination with other drugs.
Although the present study supports that the intraoperative administration of dexmedetomidine decreases the pain intensity and/or opioid consumption as well as the development of POD and POCD in patients undergoing spinal surgeries during the first 24 h postoperatively, the current literature should be expanded to allow for the safe generalisation of findings over longer follow-up periods. Further research into the neuroprotective, analgesic, and anti-inflammatory roles of DEX is warranted.
接受脊柱干预手术的患者术后疼痛发生率显著增加,这会影响其功能预后和生活质量。右美托咪定(DEX)属于中枢作用的非阿片类药物,具有高度选择性α2肾上腺素能受体激动剂活性,基于其镇痛和抗焦虑特性,常用于脊柱手术。尽管许多研究显示了DEX在术后疼痛管理中的有效性,但DEX对脊柱手术后功能改善的影响仍存在争议。
本系统评价聚焦于右美托咪定(DEX)作为镇痛剂在成人择期和急诊脊柱手术中的术中及术后作用。
通过科学网和PubMed进行电子文献检索,以评估DEX对术后疼痛管理、术后谵妄(POD)和术后认知功能障碍(POCD)的影响。
共检索到21项研究,其中3项为综述文章。对DEX的作用进行了长达术后48小时的研究。在大多数情况下,其使用与术中及术后阿片类药物消耗量减少有关。然而,由于给药方案、伴随用药、给药时间和疼痛评分系统的异质性,疼痛控制方面的研究结果尚无定论。DEX似乎能降低POD和POCD的发生率,尤其是与其他药物联合使用时。
尽管本研究支持术中给予右美托咪定可降低接受脊柱手术患者术后24小时内的疼痛强度和/或阿片类药物消耗量,以及POD和POCD的发生率,但目前的文献应进一步扩展,以便在更长的随访期内安全地推广研究结果。有必要对DEX的神经保护、镇痛和抗炎作用进行进一步研究。